gilteritinib
Japanese Regulators Approve Invivoscribe Assay as CDx for Daiichi Sankyo AML Drug
The LeukoStrat CDx FLT3 Mutation Assay can now be used in Japan as the CDx for quizartinib for the treatment of FLT3-ITD positive relapsed or refractory AML.
Researchers used Mission Bio's Tapestri assay to identify and monitor the evolution of cancer mutations in acute myeloid leukemia in response to targeted treatment.
FLT3 Inhibitor Treatment Improves Survival in Relapsed, Refractory AML Patients With Mutations
Results from the phase 3 ADMIRAL trial were announced during the American Association for Cancer Research annual meeting.
The VA decided to bring this testing in house to streamline and standardize the process for doctors and gauge markers that are relevant to the veteran population.
Invivoscribe CDx Assay Gets Expanded FDA Approval Alongside Astellas AML Drug
The LeukoStrat CDx FLT3 Mutation Assay is a PCR-based test for internal tandem duplications and tyrosine kinase domain mutations D835 and I836 in the FLT3 gene.